GHRP-6

What GHRP-6 is

GHRP-6 stands for Growth Hormone Releasing Peptide 6. The American endocrinologist Cyril Bowers described it in 1984 as a small artificial peptide of 6 amino acids that specifically releases growth hormone at the pituitary gland without also triggering the other pituitary hormones such as LH, FSH or TSH. In experiments it worked in rats, monkeys, lambs and calves.

Historically, GHRP-6 is the first member of an entire class of substances. It was followed by GHRP-1, GHRP-2 and hexarelin. And it led to a discovery: because GHRP-6 acted on a receptor for which no endogenous hormone was known, researchers searched for one. In 1996 this receptor was described in the pituitary gland and hypothalamus, and a little later the matching hormone, ghrelin from the stomach, a peptide of 28 amino acids.

How it is supposed to work

GHRP-6 docks onto the ghrelin receptor, technically GHSR-1a. This receptor sits in the pituitary gland and the hypothalamus and triggers pulses of growth hormone there. The body’s own releasing hormone GHRH acts via a different pathway. Together the two amplify each other, which was already shown in healthy men in 1990. Growth hormone in turn stimulates the liver to form IGF-1, the actual growth signal for muscles and bones.

The ghrelin receptor, however, is not only a switch for growth hormone but also for hunger. Besides growth hormone, ghrelin also stimulates appetite and food intake. Anyone who activates the receptor from outside gets both: more growth hormone and more hunger. On top of this come side effects on other hormones. At high doses, prolactin and cortisol roughly doubled.

An argument that proponents like to put forward is preserved self-regulation. Unlike injected growth hormone, GHRP-6 works via the body’s own secretion, and that remains bound to the natural brakes. The very first description already showed that the inhibiting hormone somatostatin dampens the response to GHRP-6. A 2018 review describes that growth hormone secretagogues promote pulsatile release, which is subject to negative feedback and can thereby prevent excessive levels.

What it is used for

In the scene, GHRP-6 is considered an inexpensive, time-tested peptide for boosting one’s own growth hormone secretion, often combined with a GHRH analog such as CJC-1295. The hoped-for effects are muscle building, fat loss, better recovery, better sleep and firmer skin. Because it strongly stimulates appetite, it is also used deliberately in bulking phases or by people who have difficulty gaining weight.

In research, a Cuban working group has studied GHRP-6 as a protective agent for the heart and other organs. In animal models it reduced damage after heart attack and from the cancer drug doxorubicin. This line of research is scientifically interesting but has so far been limited to animal experiments.

What users report

One effect is described almost unanimously in user circles: a strong surge of hunger shortly after injection. It fits exactly with the mechanism at the ghrelin receptor, and for the related GHRP-2 it has been measured in a controlled study: healthy men ate 35.9 percent more under the peptide than under saline. This finding says nothing about muscle building or recovery. A 2026 review names water retention as well as muscle and joint pain as typical complaints among people who self-administer growth hormone peptides.

What the studies show

Growth hormone in healthy men, 1990

Bowers and colleagues gave 18 healthy men GHRP-6 at various doses, GHRH or placebo intravenously. Growth hormone rose dose-dependently; the combination with GHRH acted synergistically. No adverse effects or laboratory abnormalities occurred due to GHRP-6. Prolactin and cortisol roughly doubled at the highest dose; LH and TSH remained unchanged.

Diagnostic test in the Lancet, 250 participants, 2000

Popovic and colleagues used the combination of GHRH and GHRP-6 as a stimulation test in 125 patients with pituitary disease and 125 healthy people. The test caused no side effects, was independent of age, sex and body fat, and separated healthy people from growth hormone deficiency better than the usual insulin hypoglycemia test. This shows how reliably GHRP-6 acts on the pituitary gland, as a single dose.

Heart attack in pigs, 2007

The Cuban group led by Berlanga occluded a coronary artery in pigs and gave GHRP-6 or saline. With GHRP-6, infarct mass was 78 percent smaller and infarct thickness 50 percent smaller, and oxidative stress was lower. An impressive animal finding that has not been tested in humans.

Where the data stop

All human data concern single doses or short studies, and what is measured is growth hormone in the blood, that is, an intermediate step. Whether repeated injections over weeks lead to more muscle mass, less fat, better recovery or better skin has not been studied in any controlled trial. The 2026 review states that direct evidence of a relevant change in body composition in humans is limited and that controlled efficacy studies are lacking.

The appetite effect, too, has not been measured for GHRP-6 itself in a dedicated human study, but for the related GHRP-2 and for ghrelin. The protective effects on the heart and organs come from animal experiments. A Cuban safety study in healthy volunteers is mentioned in the literature, but appeared only in a Spanish-language journal and could not be accessed for this page. There are no long-term data.

Status, approval and legal

GHRP-6 is not approved as a medicine in Germany or the EU and is traded as a research substance. Information on use and dosage is therefore omitted. The 2026 Prohibited List of the World Anti-Doping Agency explicitly names GHRP-6 under S2.2.4 among the growth hormone releasing peptides. The ban applies at all times, in competition and in training.

Safety

As a single dose under study conditions, GHRP-6 was well tolerated. Repeated use has not been systematically studied. Known effects are the rise in prolactin and cortisol and, for the entire class of growth hormone peptides, water retention and disturbances of blood glucose. A 2018 review names reduced insulin sensitivity as the most important concern. GHRP-6 also alters sleep: it increases light sleep in stage 2. Because growth hormone and IGF-1 promote cell growth, there is a theoretical tumor concern for which there is no clinical evidence. Anyone with diabetes or a tumor disease should not use the substance without consulting a physician. Gray-market products are untested for purity and content.

Sources

• Bowers CY et al., Endocrinology 1984 — first description of the hexapeptide
• Bowers CY et al., Journal of Clinical Endocrinology and Metabolism 1990 — growth hormone in 18 healthy men
• Howard AD et al., Science 1996 — receptor of the growth hormone secretagogues
• Popovic V et al., Lancet 2000 — GHRH plus GHRP-6 as a diagnostic test
• Cabrales A et al., European Journal of Pharmaceutical Sciences 2013 — pharmacokinetics in 9 healthy men
• Laferrère B et al., Journal of Clinical Endocrinology and Metabolism 2005 — GHRP-2 increases food intake
• Berlanga J et al., Clinical Science 2007 — GHRP-6 and heart attack in pigs
• Berlanga-Acosta J et al., Clinical Medicine Insights: Cardiology 2017 — review of protective effects
• Dominikowski A et al., Frontiers in Endocrinology 2026 — growth hormone peptides between studies and self-administration
• WADA Prohibited List 2026, officially published in the Austrian Federal Law Gazette III No. 219/2025